Urokinase-type plasminogen activator expression and Rac1/WAVE-2/Arp2/3 pathway are blocked by pterostilbene to suppress cell migration and invasion in MDA-MB-231 cells  by Ko, Hyun Suk et al.
Bioorganic & Medicinal Chemistry Letters 24 (2014) 1176–1179Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier .com/ locate/bmclUrokinase-type plasminogen activator expression and Rac1/WAVE-2/
Arp2/3 pathway are blocked by pterostilbene to suppress cell
migration and invasion in MDA-MB-231 cells0960-894X  2014 The Authors. Published by Elsevier Ltd.
http://dx.doi.org/10.1016/j.bmcl.2013.12.115
⇑ Corresponding author. Tel.: +82 2 961 0808; fax: +82 2 964 1064.
E-mail address: leook@khu.ac.kr (E.-O. Lee).
 These authors contributed equally to this study.
Open access under CC BY-NC-ND license.Hyun Suk Ko , Ji Sung Kim , Sun Mi Cho, Hyo-Jeong Lee, Kwang Seok Ahn, Sung-Hoon Kim, Eun-Ok Lee ⇑
Cancer Preventive Material Development Research Center, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Republic of Koreaa r t i c l e i n f o
Article history:
Received 12 September 2013
Revised 17 December 2013
Accepted 27 December 2013
Available online 7 January 2014
Keywords:
Pterostilbene
Migration
Invasion
uPA
NF-jB
Rac1
WAVE
Arp2/3
MDA-MB-231 cellsa b s t r a c t
Breast cancer is the most common malignancy among females, and cancer invasion and metastasis are
the leading causes of cancer death in breast cancer patients. Pterostilbene, a naturally occurring dimeth-
ylether analogue of resveratrol, has been demonstrated to possess anti-cancer effects. However, inhibi-
tory effects of pterostilbene on cell migration and invasion and its underlying mechanisms are not
fully understood. In this study, we investigated the anti-invasive mechanisms of pterostilbene in human
breast cancer cell line MDA-MB-231 cells. Pterostilbene effectively inhibited serum-induced migration
and invasion without affecting the viability of breast cancer cells. The mRNA expression and activity of
urokinase-type plasminogen activator (uPA) were markedly reduced by pterostilbene treatment. More-
over, pterostilbene attenuated nuclear factor jB (NF-jB) transcriptional activity and DNA binding of
NF-jB on uPA promoter. In addition, pterostilbene signiﬁcantly impaired the activity of Rac1 and the
expression of WASP-family verprolin-homologous protein-2 (WAVE-2) and actin-related protein 2/3
(Arp2/3). Overall, these results suggest that pterostilbene caused considerable suppression of cell migra-
tion and invasion through blocking NF-jB-mediated uPA expression and Rac1/WAVE/Arp2/3 pathway.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Breast cancer is the most common malignancy among females,1
and frequently metastasizes to bone, lymph node, brain and lung,2
which interrupts successful treatment of breast cancer. Metastasis
still considers as the signiﬁcant cause of mortality being responsi-
ble for 90% of cancer deaths.2,3
It is well characterized that urokinase-type plasminogen activa-
tor (uPA) system, which is a serine protease family and consists of
uPA, uPA receptor (uPAR) and plasminogen activator inhibitors,
plays a crucial role in breast cancer metastasis. The binding of
uPA to uPAR facilitates extracellular matrix (ECM) degradation,
angiogenesis, adhesion, migration and invasion.4–6 Duffy et al.7
ﬁrst identiﬁed the connection between uPA activity in primary
breast cancer and both tumor size and metastatic status, and dem-
onstrated that breast cancer patients with high uPA activity had a
poor disease-free interval than those with low activity. Thus, uPA
system may be a prognostic marker for aggressive breast cancer
and an ideal candidate target for cancer therapy.Rac, a member of Rho family small GTPases, plays a vital role in
controlling cell motility. Rac activates actin-related protein 2/3
(Arp2/3) complex via WASP-family verprolin-homologous proteins
(WAVEs), thereby inducing reorganization of actin cytoskeleton at
the leading edge and consequent formation of lamellipodia.8,9 Reg-
ulation of these processes is important for cancer therapy because
actin cytoskeleton reorganization is the primary mechanism of cell
motility and is dynamically occurred during cell migration.8 Zhang
et al. reported that ()-Epigallocatechin-3-gallate inhibited breast
cancer cell migration and invasion by attenuating Rac1 activity.10
Furthermore, recent study has demonstrated that Cucurbitacin E
decreased tumor cell migration by impairing Arp2/3-dependent
actin polymerization in breast cancer.11
Pterostilbene is a naturally occurring dimethylether analogue of
resveratrol and stilbene phytoalexin found in several types of
berries and grapes.12–14 Pterostilbene is reported to have the ben-
eﬁcial effects such as anti-inﬂammatory, anti-oxidant, analgesic,
anti-diabetic, and hypolipidemic activities.14–16 In addition, ptero-
stilbene has been suggested to exhibit anti-cancer potentials
including inhibition of cell proliferation and induction of apoptosis
in many different types of human cancers as effective as resvera-
trol due to their close similarity in structure.12,17–19 Few studies
demonstrated that pterostilbene had the ability to suppress cancer
cell invasion and metastasis in vitro and in vivo.17,20–22 However,
Figure 1. Cytotoxic effect of pterostilbene against MDA-MB-231 cells. Cells were
treated with the indicated concentrations of pterostilbene for 24 h, followed by
assessment for cell viability by the MTT assay. Data are shown as means ± SD of
three independent experiments by analysis of Student’s t test. ⁄p < 0.05 and
⁄⁄⁄p < 0.001 versus untreated control.
+FBS                         FBS+PTER(2)
FBS+PTER(5)                  FBS+PTER(10)
A
B
Figure 2. Pterostilbene inhibited the migration of MDA-MB-231 cells. The migra-
tion ability of cells was carried out by the wound healing assay. The conﬂuent cells
were scratched and then treated with pterostilbene in a serum-containing culture
medium for 24 h. (A) The cell were stained with Diff-Quick and then randomly
chosen ﬁelds were photographed at 100. (B) The number of cells migrated into the
scratched area was calculated as a percentage of migration. Data are shown as
means ± SD of two independent experiments by analysis of Student’s t test
⁄⁄p < 0.01 and ⁄⁄⁄p < 0.001 versus serum-treated control.
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Figure 3. Pterostilbene inhibited the invasion of MDA-MB-231 cells. The invasion
assay was performed using 48-well microchemotaxis chambers with matrigel-
coated ﬁlter for 15 h. (A) The cell were stained with Diff-Quick and then randomly
chosen ﬁelds were photographed at 100. (B) The number of cells invaded to the
lower surface was calculated as a percentage of invasion. Data are shown as
means ± SD of three independent experiments by analysis of Student’s t test
###p < 0.001 versus untreated control and ⁄⁄⁄p < 0.001 versus serum-treated control
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Figure 4. Pterostilbene reduced the mRNA expression and activity of uPA in MDA-
MB-231 cells. Cells were treated with pterostilbene for 24 h. (A) The mRNA
expression of uPA and uPAR were determined by RT-PCR analysis. GAPDH was used
as a loading control. (B) The activity of uPA was assessed using a SPECTROZYME PL
in conditioned medium from pterostilbene-treated MDA-MB-231 cells. Data are
shown as means ± SD of two independent experiments by analysis of Student’s
test. ⁄⁄⁄p < 0.001 versus untreated control..
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static spread of cancer cells are poorly performed. Pterostilbene
has some advantages to be developed into a chemopreventive
agent. When administered orally, pterostilbene showed muchuPA
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Figure 5. Pterostilbene attenuated the NF-jB activation in MDA-MB-231 cells.
(A) After transfection with NF-jB luciferase reporter construct for 18 h, the
cells were treated with pterostilbene for 24 h and then luciferase activity was
measured using a Dual-Luciferase assay system. Data are shown as means ± SD
of two independent experiments by analysis of Student’s t test. ⁄⁄p < 0.01 and
⁄⁄⁄p < 0.001 versus untreated control. (B) After treatment with pterostilbene for
24 h, ChIP assay was processed using a SimpleChIP enzymatic chromatin IP kit.
Puriﬁed DNA was analyzed by PCR using the primers speciﬁc for the NF-jB
binding site of uPA promoter region.
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Figure 6. Pterostilbene impaired the Rac1/WAVE-2/Arp2/3 pathway in MDA-MB-231 ce
using a G-LISA activity assay kit. Data are shown as means ± SD of two independent ex
control. Cells were treated with pterostilbene (B) or NSC23766 (C) for 24 h. Equal amou
antibodies.greater bioavailability and seven times longer half-life compared
with other stilbene compounds.23 It was reported that daily oral
intake of various concentrations of pterostilbene (up to 3000 mg/
kg) for 28 days did not affect body weight gain, biochemical
parameters, and histopathological alterations at any dose in
mice.24 Additionally, the safety of long-term pterostilbene admin-
istration was identiﬁed in humans up to 250 mg/day.25 These re-
sults suggest that dietary orally administration of high doses of
pterostilbene may be safe as a therapeutic agent for clinical use.
The goals of this study were to investigate the effects of ptero-
stilbene on the migration and invasion of breast cancer cell, and to
reveal the underlying molecular mechanisms of its activity in
highly invasive human breast cancer cell line, MDA-MB-231.
In order to explore the cytotoxic effect of pterostilbene against
MDA-MB-231 cells, cell viability was evaluated by the MTT assay.26
After treatment with pterostilbene for 24 h, cell viability was sig-
niﬁcantly decreased at the concentration of 20 lM and 40 lM by
6% and 40%, respectively, compared with untreated control. Ptero-
stilbene has no signiﬁcant cytotoxic effect at up to 10 lM (Fig. 1).
To exclude the possibility that the anti-invasive effects of pterostil-
bene were due to its cytotoxicity, non-cytotoxic concentrations
(610 lM) were applied in subsequent experiments.
Metastasis is the result of a multistep process involving cancer
cell adherence to ECM, proteolytic degradation of ECM, cell motil-
ity and invasion.27 To investigate the effects of pterostilbene on the
migration and invasion of breast cancer cell, the wound healing
assay26 and the invasion assay26 were carried out. Pterostilbene
strongly inhibited the number of cells migrated into the scratched
area by 25%, 59%, and 76% at 2, 5, and 10 lM, respectively (Fig. 2).
FBS caused a 3.4-fold increase in the number of cells invaded to the
lower surface, which was effectively suppressed by 20%, 29%, and2
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lls. (A) Cells were treated with pterostilbene for 30 min. Rac1 activity was assessed
periments by analysis of Student’s t test. ⁄p < 0.05 and ⁄⁄p < 0.01 versus untreated
nt of total proteins (25–30 lg) were analyzed by Western blot using the indicated
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10 lM, respectively (Fig. 3). uPA system triggers breast cancer
growth, invasion, and metastasis by its ability to degrade ECM
and basement membranes.4,28 We performed RT-PCR analysis26
and uPA activity assay29 to verify whether pterostilbene was asso-
ciated with uPA system to inhibit cell migration and invasion in
MDA-MB-231 cells. As shown in Figure 4A, pterostilbene strikingly
downregulated the mRNA expression of uPA in a dose dependent
manner. However, uPAR mRNA expression was not affected by
pterostilbene. Treatment with 5 and 10 lM of pterostilbene re-
sulted in marked decrease of 25% and 61% in uPA activity, respec-
tively (Fig. 4B).
NF-jB is a prominent transcription factor in regulating the
expression and secretion of uPA, and constitutive NF-jB activation
has been detected in many cancers including breast cancers.4,30
Previous studies have shown that inhibition of NF-jB pathway
contributed to suppress invasion and metastasis by down-
regulation of its target gene such as uPA in breast cancer cells.31,32
To clarify whether pterostilbene had an inhibitory effect on NF-jB
activation to reduce the mRNA expression of uPA, the transcrip-
tional activity of NF-jB was examined in MDA-MB-231 cells.26
Figure 5A showed that pterostilbene gradually decreased NF-jB-
dependent luciferase activity in a dose-dependent manner. To
further understand whether pterostilbene affected DNA binding of
NF-jB on uPA promoter, ChIP assay was processed.26,33 After treat-
ment with pterostilbene at 10 lM, DNA binding of NF-jB on uPA
promoter was signiﬁcantly attenuated (Fig. 5B).
Rac promotes cell migration and invasion by reorganization of
actin cytoskeleton.8,9 To determine whether inhibitory effects of
pterostilbene on cell migration and invasion were involved in
Rac signaling, we measured Rac1 activity34 and performed
Western blot26 for its downstream targets such as WAVE and
Arp2/3. Pterostilbene signiﬁcantly impaired the activity of Rac1
by 14%, 22%, and 27% at 2, 5, and 10 lM, respectively (Fig. 6A). Also,
pterostilbene dramatically decreased the expression of WAVE-2,
Arp2 and Arp3 in a dose dependent manner (Fig. 6B). To examine
the relationship between Rac1 activity and WAVE-2/Arp2/3
expression, we performed Western blot for WAVE-2/Arp2/3 after
treatment with NSC23766, a speciﬁc inhibitor of Rac activation.
As expected, the protein expressions of WAVE-2, Arp2 and Arp3
were decreased by inhibiting Rac activation (Fig. 6C).
In conclusion, we demonstrated that pterostilbene effectively
suppressed the migration and invasion of breast cancer MDA-
MB-231 cells without any cytotoxicity. Its efﬁcacy resulted from
inhibiting NF-jB-mediated uPA expression and Rac1/WAVE-2/
Arp2/3 pathway. These results support that pterostilbene has a
potential as an anti-invasive agent for metastatic breast cancer.
However, more studies are needed to further develop pterostilbene
as an anti-metastatic agent for clinical use to overcome breast
cancer metastasis.Acknowledgments
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